Assessment of ketamine effect on cancer pain and depression

Assessment of ketamine effect on cancer pain and depression - cancer and depression

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035531

Enrollment

Registered

2019-02-01

Start date

2019-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer pain

Interventions

Injection intravenous of ketamine 0.05 mg/kg and midazolam 0.04 mg/kg for 40 min

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a patient who has both cancer pain and depression

Exclusion criteria

Exclusion criteria: a patient who has allergy to ketamine and past history of high intraocular or intracranial pressure

Design outcomes

Primary

Measure	Time frame
relationship between numerical rating scale and state of depression	—

Secondary

Measure	Time frame
assessment of biomarkers	—

Countries

Japan

Contacts

Public ContactTakashi Kudo

Hirosaki University Hospital department of anesthesiology

takf5@hirosaki-u.ac.jp0172335111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026